Electrochemical Sensor Platform for Fast, Sensitive Detection of Biomarkers in Whole Blood
Written by AZoSensorsFeb 15 2021
Many life-threatening medical conditions, such as sepsis, which is triggered by blood-borne pathogens, cannot be detected accurately and quickly enough to initiate the right course of treatment.
In patients that have been infected by an unknown pathogen and progress to overt sepsis, every additional hour that an effective antibiotic cannot be administered significantly increases the mortality rate, so time is of utmost essence.
The challenge with rapidly diagnosing sepsis stems from the fact that measuring only one biomarker often does not allow a clear-cut diagnosis. Engineers have struggled for decades to simultaneously quantify multiple biomarkers in whole blood with high specificity and sensitivity for point-of-care (POC) diagnostic applications as this would avoid time-consuming and costly blood processing steps in which informative biomarker molecules
New diagnostic platform can rapidly measure COVID-19-related biomarkers
The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
The research collaboration further cements both parties commitment to bringing the Wyss multiplexed electrochemical detection system forward as a diagnostic tool during the pandemic and follows a licensing agreement coordinated by Harvard s Office of Technology Development (OTD) in November 2020 that granted The iQ Group Global non-exclusive, term-limited access to the eRapid technology in accordance with the Univer
Share this article
Share this article
BOSTON, Feb. 17, 2021 /PRNewswire/ The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard University
E-Mail
IMAGE: The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with the GBS s transistor technology in developing a multiplexed. view more
Credit: Wyss Institute at Harvard University
(BOSTON) The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
Harvard s Wyss Institute collaborates with GBS Inc on the Wyss eRapid-based COVID-19 diagnostic to help curb the pandemic apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.